Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010

The Lancet

Volumn 382, Issue 9904, 2013, Pages 1564-1574

  Degenhardt, Louisa ^a,b   Whiteford, Harvey A ^c   Ferrari, Alize J ^c   Baxter, Amanda J ^c   Charlson, Fiona J ^c   Hall, Wayne D ^d   Freedman, Greg ^e   Burstein, Roy ^e   Johns, Nicole ^e   Engell, Rebecca E ^e   Flaxman, Abraham ^e   Murray, Christopher J L ^e   Vos, Theo ^e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; CANNABIS; COCAINE; ILLICIT DRUG; OPIATE;

ADOLESCENT; ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; AUSTRALIA; CANNABIS ADDICTION; CHILD; COCAINE DEPENDENCE; DISABILITY ADJUSTED LIFE YEARS; DRUG DEPENDENCE; DRUG USE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INFANT; INTERNET; INTRAVENOUS DRUG ABUSE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEWBORN; OPIATE ADDICTION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RUSSIAN FEDERATION; SCHOOL CHILD; UNITED KINGDOM; UNITED STATES; YEARS OF LIFE LIVED WITH DISABILITY; YEARS OF LIFE LOST;

EID: 84887248421     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61530-5     Document Type: Article

References (47)

1. Babor TF, Caulkins J, Edwards G, et al, eds. Drug policy and the public good. Oxford: Oxford University Press, 2010.
2. McAllister WB, ed. Drug diplomacy in the twentieth century. London: Routledge, 2000.
3. WHO. The ICD-10 classification of me ntal and behavioural disorders - diagnostic criteria for research. Geneva: World Health Organization, 1993.
4. Kessler R, Üstün T. The WHO World Mental Health Surveys: global perspectives on the epidemiology of mental disorders. Cambridge: Cambridge University Press, 2008.
5. World Bank. World development report 1993: Investing in Health. New York: Oxford University Press, 1993.
6. Murray CJL, Lopez AD, eds. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. USA: World Health Organization, Harvard School of Public Health, World Bank, 1996.
7. Lopez AD, Mathers C, Ezzati M, Jamison D, Murray C. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57.
8. WHO. The global burden of disease: 2004 update. Geneva: World Health Organization, 2008.
9. Degenhardt L, Hall W, Lynskey M, Warner-Smith M. Chapter 13. Illicit drug use. In: Ezzati M, Lopez AD, Rodgers A, Murray R, eds. Comparative quantification of hea lth risks: global and regional burden of disease attributable to selected major risk factors, 2nd edn. Geneva: World Health Organization, 2004: 1109-76.
10. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379: 55-70.
11. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injurie s in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223.
12. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-60.
13. WHO. The ICD-10 classification of mental and behavioural disorders - diagnostic criteria for research. Geneva: World Health Organization, 1993.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th edition - technical revision). Washington, DC: American Psychiatric Association, 2000.
15. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2129-43.
16. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-96.
17. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
18. Bucello C, Degenhardt L, Calabria B, et al. What do we know about the extent of cocaine use and dependence? Results of a global systematic review. NDARC technical report no. 308. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2010.
19. Calabria B, Degenhardt L, Nelson P, et al. What do we know about the extent of cannabis use and dependence? Results of a global systematic review. NDARC technical report no. 307. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2010.
20. Degenhardt L, Calabria B, Nelson P, et al. What do we know about the extent of meth/amphetamine use and dependence? Results of a global systematic review. NDARC technical report no. 310. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2010.
21. Nelson P, McLaren J, Degenhardt L, et al. What do we know about the extent of heroin and other opioid use and dependence? Results of a global systematic review. NDARC technical report no. 309. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2010.
22. Degenhardt L, Larance B, Mathers B, et al. Benefits and risks of pharmaceutical opioids: essential treatment and diverted medication. A global review of availability, extra-medical use, injection and the association with HIV. Sydney: University of New South Wales, 2008.
23. Degenhardt L, Bucello C, Calabria B, et al. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend 2011; 117: 85-101.
24. Calabria B, Degenhardt L, Briegleb C, et al. Systematic reviews of prospective studies investigating "remission" from amphetamine, cannabis, cocaine and opioid dependence. Addict Behav 2010; 35: 741-49.
25. Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 2010; 29: 318-30.
26. Degenhardt L, Singleton J, Calabria B, et al. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend 2011; 113: 88-95.
27. Singleton J, Degenhardt L, Hall W, Zabransky T. Mortality among people who use amphetamines: a systematic review of cohort studies. Drug Alcohol Depend 2009; 105: 1-8.
28. Mathers B, Degenhardt L, Bucello C, Lemon J, Hickman M, Wiessing L. Mortality among people who inject drugs: a meta-analytic review. Bull World Health Organ 2013; 91: 102-23.
29. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011; 106: 32-51.
30. Calabria B, Phillips B, Singleton J, et al. Searching the grey literature to access information on drug and alcohol research - a resource to identify drug related databases and websites. National Sydney: Drug and Alcohol Research Centre, University of New South Wales, 2009.
31. Ali H, Calabria B, Phillips B, et al. Searching the grey literature to access information on drug, alcohol and HIV/AIDS research: an update. NDARC technical report no. 314. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2010.
32. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4: 1628-54.
33. Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr 2003; 1: 4.
34. Mont D. Measuring health and disability. Lancet 2007; 369: 1658-63.
35. US NIH National Institute on Alcohol Abuse and Alcoholism. National Epidemiologic Survey on Alcohol and Related Conditions Wave 1 and Wave 2. Bethesda, MD: National Institutes of Health. http://pubs.niaaa.nih.gov/ publications/arh29-2/74-78.htm (accessed July 25, 2013).
36. Australian Bureau of Statistics. National survey of mental health and wellbeing of adults 1997. Canberra, Australia: Australian Bureau of Statistics, 2008.
37. WHO. Age standardization of rates: a new WHO standard. http://www.who.int/healthinfo/paper31.pdf (accessed July 22, 2013).
38. Ferrari AJ, Saha S, McGrath JJ, et al. Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 Study. Popul Health Metr 2012; 10: 16.
39. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
40. Nelson P, Mathers B, Cowie B, et al. The epidemiology of viral hepatitis among people who inject drugs: results of global systematic reviews. Lancet 2011; 378: 571-83.
41. UNODC. World drug report 2012. Vienna: United Nations, 2012.
42. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376: 285-301.
43. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 1978-88.
44. Swan T. The hepatitis C treatment pipeline report. http://www. treatmentactiongroup.org/uploadedFiles/About/Publications/TAG-Publications/2011/ HCV%20pipeline%202011%20final.pdf (accessed June 18, 2011).
45. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev 2001; 4: CD003022.
46. Denis C, Lavie E, Fatseas M, Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev 2013; 6: CD005336.
47. Knapp W, Soares B, Farrel M, Lima M. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev 2007; 3: CD003023.